European Society For Medical Oncology

ESMO’s input to Preparedness 2.0 - the World Health Organisation Regional Office for Europe Strategy for Health Emergency Preparedness, Response, and Resilience (2024–2029) -  is reflected in the final text adopted by the 53 WHO Europe Member States at the 74th Regional Committee meeting

Evidence for efficacy is based on the results from the LIBRETTO-531 study

The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works

New indication concerns the treatment of patients with early breast cancer at high risk of recurrence

Findings from the SWOG S1011 study

Findings from the INTERLACE study

Findings from the S1826 study

The forthcoming FP10 programme holds enormous potential to boost cancer research in Europe and help achieve the goals of Europe’s Beating Cancer Plan and the Mission on Cancer. ESMO is listed among the contributors to the Heitor Report and supports its recommendation to allocate  €220 billion to FP10

Evidence for efficacy is based on the results from the LIBRETTO-531 study

New indication concerns the treatment of patients with early breast cancer at high risk of recurrence

Findings from the SWOG S1011 study

Findings from the INTERLACE study

Findings from the S1826 study

Evidence for efficacy is based on the results from the MARIPOSA-2 study

Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study

Findings from the CABINET study

Findings from a pooled analysis of randomised controlled trial data

The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand

The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers

The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world

Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment

The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works

Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas

ESMO is pleased to announce the 2024 ESMO Fellowship awardees

The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)

The recipients of the 2024 ESMO Society Awards have been announced today by ESMO

Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research

The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics

ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.

Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care